Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Boston, USA-based Ratio Therapeutics has completed a $50 million series B financing, bringing the total raised by the company so far to over $90 million. 18 January 2024
Two new initial public offerings (IPO) are set to go ahead in the USA, raising hopes of a thaw in what has been a long winter for biotech companies going public. 17 January 2024
Washington University in Missouri, USA, has joined forces with the life sciences investment company Deerfield Management to launch a new R&D venture. 17 January 2024
Just a month after winning its first US approval for sickle cell disease (SCD), Casgevy (exagamglogene autotemcel [exa-cel]) has won a second Food and Drug Administration (FDA) approval. 17 January 2024
California, USA-based biotech Allakos yesterday announced disappointing top-line data from its Phase II clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase IIb clinical trial in patients with chronic spontaneous urticaria (MAVERICK). 17 January 2024
Shares of US clinical-stage biotech Aclaris Therapeutics shot up as much as 40% to $1.21 in early trading today, after it announced leadership changes and that it is undertaking a strategic review of its business. 16 January 2024
Switzerland-based Stalicla, a biopharma advancing precision medicine pipelines for neuropsychiatric and neurological disorders, has announced the successful completion of the first closing of its Series B financing round, securing $17.4 million. 16 January 2024
New York, USA-based rare neurological disease drug developer Neurogene has announced the appointment of Julie Jordan as its chief medical officer (CMO). 16 January 2024
Food and healthcare company Orion Group has made a bold step to expand its biotech interests, buying around a quarter of LegoChem Biosciences (Kosdaq: 141080) for $420 million. 16 January 2024
DISCO Pharmaceuticals, a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, today emerges from stealth. 16 January 2024
Belgian biotech BioSenic has reached agreement on a binding term sheet with privately-held Australian firm Phebra on the development of the first oral formulation of arsenic troxide for chronic graft versus host disease (cGvHD) treatment. 15 January 2024
Shanghai-headquartered JiXing Pharmaceuticals has announced the acquisition of US biotech major Biogen’s (Nasdaq: BIIB) BIIB131 for global clinical development. 15 January 2024
Massachusetts, USA-based Dyne Therapeutics has raised $345 million, shortly after announcing encouraging biomarker data for its Duchenne muscular dystrophy (DMD) candidate. 15 January 2024
HilleVax (Nasdaq: HLVX) has agreed terms for a licensing deal with Chengdu-based Kanghua Biological, a Chinese biotech also known as Kangh. 12 January 2024
California, USA-based biotech start-up TORL BioTherapeutics has appointed of Mark Alles, currently executive chairman, to the additional post of chief executive (CEO). 12 January 2024
After an initial dip, BioInvent International saw its shares close up 1.2% at 17.22 kronor today, when the Swedish biotech revealed that a licensing partner was pulling out of their agreement. 12 January 2024
Shares of USA-based was Xeris Biopharma (were up 12% to $2.67 in morning trading yesterday, after it announced a licensing deal with biotech major Amgen. 12 January 2024
The New Drug Application (NDA) for China-based Hutchmed’s sovleplenib as a treatment of adult patients with primary immune thrombocytopenia (ITP) has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA). 11 January 2024
China’s Shanghai Henlius Biotech today announced a strategic collaboration with USA-based Sermonix Pharmaceuticals for exclusive rights to develop, manufacture and commercialize Sermonix’ lead investigational drug, lasofoxifene, in China. 11 January 2024
A major equity investment will see Germany’s Bayer and New York-based life science investor RTW Investments take a stake in a Chinese biotech working on heart and eye conditions. 11 January 2024